Current oncology最新文献

{"title":"Cerebral Amyloid Angiopathy-Related Inflammation Mimicking Leptomeningeal Metastasis After Resected Lung Adenocarcinoma: A Case Report Highlighting Dynamic Diagnostic Reassessment.","authors":"Kodai Shigeyama, Yosuke Dotsu, Shunsuke Yoshimura, Takeshi Hiu, Nozomi Ueki, Ryo Futsuki, Satoru Koga, Noritaka Honda, Kazumasa Akagi, Midori Matsuo, Hirokazu Taniguchi, Shinnosuke Takemoto, Hiroshi Mukae","doi":"10.3390/curroncol33090562","DOIUrl":"10.3390/curroncol33090562","url":null,"abstract":"<p><p>Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a rare inflammatory subtype of cerebral amyloid angiopathy that may present with leptomeningeal enhancement on magnetic resonance imaging (MRI), thereby mimicking leptomeningeal metastasis (LM) in patients with cancer. We report the case of an 82-year-old woman with a recently resected lung adenocarcinoma who underwent brain MRI following a fall. MRI revealed bilateral asymmetric white matter hyperintensities and multifocal leptomeningeal enhancement, which initially suggested LM. However, preserved neurological function, negative cerebrospinal fluid cytology, and the subsequent identification of numerous cortical and subcortical microbleeds on targeted reassessment with susceptibility-weighted MRI prompted diagnostic reassessment. Brain biopsy demonstrated vascular amyloid deposition with perivascular inflammatory infiltrates, confirming CAA-ri. Because the patient remained neurologically stable, she was managed conservatively, and spontaneous radiological improvement was observed during follow-up. This case highlights the fact that leptomeningeal abnormalities in patients with lung cancer do not invariably represent leptomeningeal metastasis. When clinicoradiological findings are discordant, prompt reassessment using appropriately selected MRI sequences should be integrated with cerebrospinal fluid analysis and multidisciplinary evaluation, with pathological confirmation considered when clinically consequential alternative diagnoses cannot be excluded. This approach may help avoid inappropriate LM-directed therapy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of Preoperative Prognostic Nutritional Index and Modified Surgical Apgar Score for Severe Postoperative Complications in Malignant Obstructive Jaundice.","authors":"Shiwei Wu, Jiawei Jin, Dongxing Zhang, Daobin Wang, Jiayue Zou, Xiaoyuan Hu, Jun He, Xiaofeng Xue, Lei Qin","doi":"10.3390/curroncol33090560","DOIUrl":"10.3390/curroncol33090560","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the predictive value of preoperative prognostic nutritional index (PNI) and intraoperative modified surgical Apgar score (mSAS) for severe complications (Clavien-Dindo grade ≥ III) after curative-intent surgery in patients with malignant obstructive jaundice (MOJ) and to construct a nomogram prediction model.</p><p><strong>Methods: </strong>The clinical data of 308 patients who underwent curative-intent surgery for MOJ at the First Affiliated Hospital of Soochow University from January 2019 to January 2024 were retrospectively collected. Independent predictive factors were screened using univariate and multivariate logistic regression; the dose-response relationship between PNI and complication risk was analyzed using restricted cubic spline (RCS); subgroup analysis was conducted to evaluate the consistency of predictive effects; procedure-specific sensitivity analyses were performed separately for patients undergoing pancreaticoduodenectomy (PD) and hepatectomy with extrahepatic bile duct resection (HCAE); a nomogram was constructed based on the independent predictive factors, and the performance of the model was evaluated using receiver operating characteristic (ROC), calibration curve, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Among the 308 patients, 65 (21.1%) had severe complications. The PNI (40.30 ± 4.19 vs. 45.91 ± 4.75) and mSAS (5.28 ± 1.28 vs. 7.28 ± 1.34) in the severe complication group were significantly lower than those in the non-severe complication group (all <i>p</i> < 0.001). After multivariable adjustment including surgical approach, higher PNI (OR = 0.73, 95% CI 0.66-0.82, <i>p</i> < 0.001) and higher mSAS (OR = 0.30, 95% CI 0.21-0.44, <i>p</i> < 0.001) were independently associated with lower odds of severe complications. The quartile analysis of PNI showed a graded inverse association (<i>p</i> for trend < 0.001). Multivariable-adjusted RCS analysis demonstrated a significant overall inverse association between PNI and severe complication risk (<i>p</i> for overall < 0.001), with no significant evidence of nonlinearity (<i>p</i> for nonlinearity = 0.425). In procedure-specific sensitivity analyses, the PNI-mSAS model achieved an AUC of 0.959 (95% CI 0.921-0.997) in the PD subgroup and 0.901 (95% CI 0.837-0.965) in the HCAE subgroup. The AUC of the nomogram prediction model was 0.924; the calibration curve indicated good agreement, and DCA suggested potential clinical utility.</p><p><strong>Conclusion: </strong>Preoperative PNI and intraoperative mSAS are independently associated with severe complications after curative-intent surgery in patients with MOJ. The PNI-mSAS nomogram showed good internal discrimination and calibration and may assist perioperative risk stratification; however, external validation is required before routine clinical application.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berubicin Substituted for Cytarabine in a MATRix-Based Regimen for Isolated Central Nervous System Lymphoma: A Five-Patient Case Series from the BER-PUM Study.","authors":"Sławomir Milczarek, Oliwia Piotrowska, Bartłomiej Baumert, Ewa Borowiecka, Krzysztof Sommerfeld, Alina Hnatyszyn, Bogusław Machaliński","doi":"10.3390/curroncol33090557","DOIUrl":"10.3390/curroncol33090557","url":null,"abstract":"<p><p>Primary and isolated secondary central nervous system lymphomas are aggressive malignancies requiring effective central nervous system-directed therapy. Intensive high-dose methotrexate-based regimens may be difficult to deliver, particularly in older or functionally impaired patients. Berubicin is a doxorubicin analog developed to cross the blood-brain barrier. We report a prospective case series of five adults with primary or isolated secondary CNS lymphoma treated within the BER-PUM phase Ib/II study (EudraCT 2021-006028-41), evaluating berubicin as part of the investigational MBTRIX regimen. Patients received up to four 21-day cycles of rituximab, high-dose methotrexate, berubicin, and thiotepa, with between-patient and intrapatient berubicin dose escalation. Four out of five patients completed all planned cycles, even though most of the patients had an ECOG score of 2. After two cycles, four achieved partial response, and one had progressive disease. Two patients underwent autologous stem-cell transplantation; one achieved complete response maintained at 12 months, whereas the other died from severe infectious and multiorgan complications. All patients experienced at least one grade ≥ 3 adverse event, predominantly hematologic. No protocol-defined dose-limiting toxicity or berubicin dose reduction occurred. Recruitment ended prematurely because berubicin became unavailable. This case series demonstrates the feasibility of MBTRIX, although the small sample and incomplete dose escalation preclude definitive conclusions regarding safety and efficacy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>FGFR2</i> Fusions in Pancreatobiliary and Ampullary Cancers: High Detection Rate in FFPE Specimens of Intrahepatic Cholangiocarcinoma with Limited RNA Yields Using Amplicon-Based NGS Assay.","authors":"Simon Guertin, Niloofar Sina, Ken Kron, Kenneth J Craddock, Amy McCarty, David M Hwang, Weei-Yuarn Huang","doi":"10.3390/curroncol33090559","DOIUrl":"10.3390/curroncol33090559","url":null,"abstract":"<p><p>Fibroblast growth factor receptor 2 (FGFR2) fusions are identified in approximately 10-16% of patients with intrahepatic cholangiocarcinoma (iCCA) and represent actionable targets, with several FGFR inhibitors approved for clinical use. To evaluate the clinical utility and assay performance of an amplicon-based next-generation sequencing (NGS) approach in this setting, we assessed <i>FGFR2</i> fusion detection using the Oncomine Comprehensive Assay Plus (OCA-P). A total of 75 formalin-fixed paraffin-embedded (FFPE) specimens from biliary, pancreatic, and ampullary malignancies submitted for FGFR2 fusion testing between 1 March 2023 and 30 June 2024 were retrospectively analyzed, including 40 cases of iCCA. All iCCA specimens were successfully analyzed. <i>FGFR2</i> fusions were detected exclusively in iCCA, yielding a detection rate of 20%. RNA concentrations in iCCA specimens ranged from 0.02 ng/µL to 104 ng/µL; six cases (15%) exhibited yields below 1 ng/µL and 10 cases (25%) ranged between 1 and 2 ng/µL. Despite limited RNA input, OCA-P demonstrated robust performance, successfully identifying <i>FGFR2</i> fusions at concentrations below 2 ng/µL, levels typically considered suboptimal for partner-agnostic NGS approaches. These findings support the robustness and clinical utility of the OCA-P assay for reliable <i>FGFR2</i> fusion detection in iCCA, particularly in specimens with limited RNA input.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Carcinoma with Exocrine and Neuroendocrine Components: A 16-Year Cohort Analysis and International Comparison.","authors":"Hu Ren, Zelin Wen, He Fei, Penghui Niu, Zefeng Li, Diliyaer Adili, Dongbing Zhao","doi":"10.3390/curroncol33090558","DOIUrl":"10.3390/curroncol33090558","url":null,"abstract":"<p><p><b>Background:</b> Gastric carcinoma with coexisting exocrine and neuroendocrine components (GC-EN) is rare and clinically aggressive, but its temporal pattern and prognostic impact remain poorly characterized. <b>Materials and Methods:</b> We retrospectively analyzed 1043 patients who underwent curative gastrectomy at our center between 2008 and 2024. Following tumor-node-metastasis staging and 1:2 pTNM stage matching, 882 patients were included; 294 had GC-EN, of which 175 had GNEC, and 588 had GC. Clinicopathological characteristics were compared, survival outcomes were assessed using Kaplan-Meier estimates and multivariate Cox regression, and the proportion of GNEC cases in our center and the U.S. surveillance, epidemiology, and end results (SEER) database were evaluated. Survival patterns of GNEC were further compared with published international cohorts using Engauge Digitizer software. <b>Results:</b> Among the patients with gastric cancer admitted for treatment, the proportion of NEC fluctuated between 4.01% and 4.38% (2008-2013) and finally dropped to 1.6% (2020-2021), whereas the SEER database showed a modest rise with a late dip (1.67% → 2.72% → 2.44%). The overall survival (OS) of patients with NEC appeared to improve at our center (1-/2-/3-year OS: 85.1%/59.6%/34% in 2008-2012 to 94.1%/87.5%/76.2% in 2021-2024), whereas that in the SEER database declined over the same periods. The 5-year OS of the two databases remained similar (42.7% vs. 41.0%). The 1, 2 and 5-year survival rates of NEC in the external cohorts were higher than those in the SEER and Berlin series; however, the 3-year survival rates were similar, with the Italian multicenter cohort performing the worst. The Kaplan-Meier analysis demonstrated significantly worse OS for GC-EN versus GC (<i>p</i> < 0.001); within GC-EN, the NEC subgroup (NEC ≥ 70%) had the poorest outcomes (<i>p</i> < 0.001), whereas mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) and adenocarcinoma-dominant (AC-dominant) cases had similar outcomes as GC (<i>p</i> = 0.52, <i>p</i> = 0.81). In the multivariable Cox model, GC-EN histology remained independently associated with worse OS (HR = 1.49, 95% CI 1.15-1.92; <i>p</i> < 0.01). Metastatic lymph node burden and higher pTNM stage were associated with worse survival, whereas greater lymph node retrieval and age 40-65 years were protective. After adjustment, vascular invasion, tumor size, and location were not independently significant. <b>Conclusions:</b> Over the past 16 years at the National Cancer Center of China, the proportion of NEC cases decreased, and survival appeared to improve. NEC-dominant disease appeared to be the main driver of poor prognosis within GC-EN, whereas MiNEN and AC-dominant tumors showed survival patterns similar to GC in this cohort. These findings emphasize the need for GC-EN-specific risk stratification and tailored treatment strategies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast-Ovarian Hereditary Cancer Syndrome: Beyond <i>BRCA1</i> and <i>BRCA2</i>.","authors":"Evgeny Imyanitov, Anna Sokolenko","doi":"10.3390/curroncol33090556","DOIUrl":"10.3390/curroncol33090556","url":null,"abstract":"<p><p>Although <i>BRCA1</i> and <i>BRCA2</i> remain the backbone for germline DNA testing of patients with breast cancer (BC) or ovarian cancer (OC), there are a number of other genes with proven or potential clinical significance. <i>PALB2</i> is associated with an elevated risk of BC, whereas pathogenic variants (PVs) in <i>RAD51C</i>, <i>RAD51D</i>, and <i>BRIP1</i> are mainly relevant to OC development. Some germline findings are helpful in guiding therapeutic decisions: for example, <i>PALB2</i>, <i>RAD51C</i>, and <i>RAD51D</i> germline PVs render tumors sensitive to PARP inhibitors (PARPi), whereas cancers arising in <i>PTEN</i> heterozygotes are likely to be responsive to AKT down-regulators. <i>CHEK2</i>, <i>ATM</i>, <i>BLM</i>, and <i>NBN</i> PVs result in only a two-fold or even lower excess of cancer risk. However, the incorporation of these genes in DNA testing panels may occasionally lead to the identification of individuals with biallelic germline inactivation; these patients have a severe disease phenotype and thus require intensive medical intervention. The accumulation of data on \"non-<i>BRCA</i>\" BC- and OC-predisposing genes is complicated due to the rarity of their alterations, significant interethnic variations in population frequency of relevant PVs, heterogeneity of disease subtypes, etc. The use of extended gene panels, which pool together both clinically validated cancer-associated genes and \"candidate\" genes with potential but unproven significance, is likely to be a prevailing diagnostic approach in the next few years; therefore, proper attitudes towards accumulation and interpretation of genetic data are important.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Implications of Recurrence Patterns and Time to Recurrence in Post-Hepatectomy Hepatocellular Carcinoma Recurrence: An Exploratory Analysis.","authors":"Jianwei Chen, Wenhao Teng, Mingji Zhang, Xiaolong Wang, Yuemin Zhu, Liting Wen, Juyi Wu, Dechun Zheng, Zhuting Fang","doi":"10.3390/curroncol33090555","DOIUrl":"10.3390/curroncol33090555","url":null,"abstract":"<p><p>Post-recurrence survival (PRS) after hepatectomy for hepatocellular carcinoma (HCC) varies widely, yet the prognostic significance of the recurrence pattern and time to recurrence (TTR) for PRS remains incompletely defined. This single-center retrospective study included 126 patients with first HCC recurrence after curative hepatectomy (2018-2024) and aimed to explore the prognostic role of recurrence pattern, classified as low-risk (oligo-recurrence: ≤3 intrahepatic nodules, each ≤3 cm) or high-risk (multiple/large intrahepatic, tumor in vein, or extrahepatic), for PRS. In the overall cohort, the recurrence pattern independently predicted PRS (hazard ratio 2.13, <i>p</i> = 0.015); the preoperative Barcelona Clinic Liver Cancer (BCLC) stage, gamma-glutamyl transferase, and total bilirubin were also independent predictors. A sensitivity analysis, including post-recurrence treatment, attenuated the hazard ratio for high-risk pattern to 1.82 (95% CI 0.93-3.55, <i>p</i> = 0.079), consistent with partial mediation. Kaplan-Meier analyses suggested an association between shorter TTR and worse overall survival (OS), but this finding is descriptive because OS measured from surgery is mathematically coupled with TTR. In an exploratory subgroup analysis of patients with early-stage primary HCC (BCLC 0/A, <i>n</i> = 98), the recurrence pattern showed a borderline association with PRS (<i>p</i> = 0.053). Late detection was associated with high-risk recurrence but did not independently affect survival. These findings highlight the prognostic value of the recurrence pattern for PRS and support the consideration of TTR as a descriptive prognostic indicator, which together may inform risk-adapted follow-up and treatment strategies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Epidemiology and Decentralization Service Program Initiation: A Cross-Sectional Analysis of Hospital-Based Oncology Admissions and Cancer Service Disparities.","authors":"Zukiswa Jafta, Muambangu Jean Paul Milambo, Wilson Wezile Chitha","doi":"10.3390/curroncol33090552","DOIUrl":"10.3390/curroncol33090552","url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a growing public health challenge globally, with increasing demand for oncology services, particularly in resource-limited settings. In South Africa's Eastern Cape Province, tertiary hospitals face rising patient loads amid constrained infrastructure and late-stage presentation. This study assessed temporal trends, gender differences, and cancer-type distribution in oncology service utilisation at Nelson Mandela Academic Hospital (NMAH) from April 2023 to February 2025.</p><p><strong>Methods: </strong>A retrospective quantitative observational time-series design was used. Monthly aggregated oncology service data were extracted from hospital records, including total cancer attendances, gender distribution, cancer types, and service utilisation indicators (new cases, follow-ups, chemotherapy, hormone therapy, palliative care, admissions, referrals, and mortality). Descriptive statistics, Pearson correlation, and simple linear regression were applied to assess temporal trends. Time (months) was the independent variable.</p><p><strong>Results: </strong>A total of 16,368 cancer-related encounters were recorded, with a mean of 706.4 cases per month. Females accounted for 11,816 cases, significantly exceeding males (4552). Breast cancer was the most prevalent malignancy (5763 cases), followed by other cancers (4316) and cervical cancer (3616). Cervical cancer demonstrated a strong and statistically significant increasing trend (r = 0.619, <i>p</i> = 0.002), while lung cancer also showed a significant upward trend (r = 0.549, <i>p</i> = 0.007). Breast cancer showed a positive but non-significant trend (<i>p</i> = 0.163), whereas prostate and oesophageal cancers showed no significant temporal changes. Service utilisation was dominated by follow-up visits (14,761) and palliative care (16,911), indicating a high burden of advanced disease. Overall attendance showed an increasing trend, peaking at 1039 cases in April 2024, with seasonal declines in December-January.</p><p><strong>Conclusions: </strong>Oncology service utilisation at NMAH is increasing, with marked gender disparities and rising trends in cervical and lung cancers. The high reliance on palliative and follow-up care highlights late presentation and advanced disease burden. Strengthening early detection, screening programmes, and decentralised oncology service capacity is essential to address the growing cancer burden in this setting.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605038/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental Value of PI-RADS v2.1 for Adverse Pathology at Radical Prostatectomy: A Retrospective 1.5-T MRI Cohort.","authors":"Yunus Kayali, Onur Erdemoglu, Yigit Kudret Akyol, Melih Colak, Alpcan Torun, Fatih Bicaklioglu, Bilal Eryildirim","doi":"10.3390/curroncol33090554","DOIUrl":"10.3390/curroncol33090554","url":null,"abstract":"<p><p>The incremental value of PI-RADS for predicting adverse pathology at radical prostatectomy in men diagnosed through systematic biopsy remains uncertain. We assessed whether PI-RADS improves discrimination beyond age, MRI-derived prostate-specificantigen density (PSAD), biopsy Grade Group, and quantitative biopsy tumour burden. This retrospective study included 284 men undergoing 1.5-T mpMRI, systematic biopsy, and radical prostatectomy between January 2020 and January 2026. Adverse pathology comprised prostatectomy Grade Group ≥ 3 and/or stage ≥ pT3a. Three logistic models were compared: age/PSAD/biopsy grade/tumour burden; age/PSAD/PI-RADS; and their combination. Internal validation used 2000 bootstrap samples. Adverse pathology occurred in 143 patients (50.4%). Apparent AUCs were 0.790 (95% CI 0.737-0.843), 0.713 (0.653-0.773), and 0.799 (0.747-0.851); optimism-corrected AUCs were 0.781, 0.703, and 0.787. Adding PI-RADS ≥ 4 yielded an adjusted OR of 1.996 (95% CI 1.150-3.465) and an apparent AUC difference of 0.009 (95% CI -0.015 to 0.033; descriptive DeLong <i>p</i> = 0.469). The combined model had a corrected calibration slope of 0.915 and Brier score of 0.187. PI-RADS from routine 1.5-T mpMRI was independently associated with adverse pathology, but its incremental discrimination beyond clinical and systematicbiopsy variables was small and uncertain. These findings concern a surgery-selected systematicbiopsy pathway, do not estimate the overall value of MRI, and require external validation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life in Ukrainian Children and Adolescents with Cancer Relocated to Switzerland During the Russian-Ukrainian War: An Exploratory Multicenter Study.","authors":"Rahel Kasteler, Ahmed Farrag, Andreas Klein-Franke, Calogero Mazzara, Francesco Ceppi, Cornelia Vetter, Nicolas von der Weid, Katrin Scheinemann","doi":"10.3390/curroncol33090553","DOIUrl":"10.3390/curroncol33090553","url":null,"abstract":"<p><p>The war in Ukraine, beginning in February 2022, disrupted continuous medical care for Ukrainian childhood and adolescent cancer patients (UCC), many of whom were relocated to pediatric cancer centers worldwide, including Switzerland. In this Brief Report, we describe their health-related quality of life (HRQoL) after arrival. In a multicenter, cross-sectional survey across five Swiss pediatric oncology centers, we included patients ≤18 years at diagnosis who arrived after 24 February 2022 and were undergoing active treatment. HRQoL was assessed by the PedsQL™ 4.0 Generic Core Scales (self- and parent-reports). Fourteen of 23 eligible families (61%) participated. HRQoL declined with age, particularly in physical functioning, while psychosocial functioning remained relatively stable but lower among adolescents; parent scores closely matched self-reports. Scores were referenced against a published cohort of healthy Ukrainian children and previously reported pediatric cancer populations. Given the small sample and lack of a matched control group, the findings cannot separate the effects of displacement, cancer, and treatment and are hypothesis-generating. They suggest a potential role for age-tailored supportive care in displaced children with cancer and call for larger, controlled studies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"33 9","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13605239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}